 |
|
CLINICIAN'S CORNER
Renal Cell Carcinoma
Brendan D. Curti, MD
JAMA. 2004;292:97-100.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancy and 90% to 95% of neoplasms arising from the kidney.1 It is the sixth leading cause of cancer death in the United States.2 Approximately 31 200 new cases of RCC were diagnosed in the United States in 2000 and more than 11 900 affected individuals died. This disease often presents with few symptoms but it can have diverse paraneoplastic manifestations. It displays relative resistance to radiation and chemotherapy, although there have been occasional durable responses to interleukin 2 (IL-2)–based immunotherapy. Recent insights into the genetic changes associated with RCC have provided new targets for therapy.
Clinical Presentation
Renal cell carcinoma is a challenging diagnosis. It often remains clinically occult for most of its course.The simultaneous presence of the classic clinical triad of flank pain, hematuria, and flank mass is uncommon (10%) and is indicative of advanced . . . [Full Text of this Article]
Genetic Factors
Histologic Findings
Treatment Modalities
Surgical Care
Surgery in Metastatic Disease
Biological Therapies
Treatments in Development
Radiation Therapy
Prognosis
Conclusions
Author Affiliation: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Ore.
RELATED LETTER
Nephron-Sparing Surgery and Renal Cell Carcinoma
Jonathan C. Routh, Bradley C. Leibovich, Horst Zincke, and Micheal L. Blute
JAMA. 2004;292(14):1684.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Kidney Cancer
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2004;292(1):134.
EXTRACT
| FULL TEXT
|
